Tahami Elham, Akbari Abolfazl, Nekouian Reza
Department of Biotechnology, Iran University of Medical Sciences, Tehran, Iran.
Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
Cancer Rep (Hoboken). 2025 Sep;8(9):e70321. doi: 10.1002/cnr2.70321.
Employing a panel of biomarkers may enable the early diagnosis of colorectal cancer. Among these biomarkers, long non-coding RNAs (LncRNAs) and microRNAs (miRNAs) are significant due to their crucial roles in biological and metabolic processes.
Therefore, the objective of this research was to evaluate the diagnostic value of the biomarkers LncRNA-xloc-000303, lncRNA-LOC152578, and miR-29a in the pre-treatment stage of colorectal cancer in Iranian patients.
In this study, 30 tumor tissue samples and 30 adjacent healthy tissue samples were collected, and RNA was extracted using the Trizol kit. Subsequently, the relative expression of the candidate microRNA and LncRNAs was analyzed using real-time PCR. The obtained gene expression data were then analyzed using REST software.
In this study, it was found that the expression of LncRNA-xloc-000303 in tumor tissues significantly increased compared to healthy tissue (p < 0.001). Additionally, the analysis revealed that the expression level of lncRNA-LOC152578 showed an increase in tumor tissues compared to healthy tissues (p = 0.57), although these changes were not statistically significant. The results of the hsa-miR-29a expression analysis indicated a down regulation in tumor tissues compared to healthy tissues; however, this change was also not statistically significant (p = 0.34).
The results indicated that the expression changes of LncRNA-xloc-000303 in cancer tissue were significant compared to adjacent healthy tissue, suggesting its potential use as a biomarker for diagnosing colorectal cancer. However, further studies are needed to evaluate the biomarker specificity of lncRNA-LOC152578 and hsa-miR-29a. This study was conducted in an Iranian population and its results can be used in the future for personalized medicine in the prevention and treatment of colorectal cancer.
使用一组生物标志物可能有助于结直肠癌的早期诊断。在这些生物标志物中，长链非编码RNA（LncRNAs）和微小RNA（miRNAs）因其在生物和代谢过程中的关键作用而具有重要意义。
因此，本研究的目的是评估生物标志物LncRNA-xloc-000303、lncRNA-LOC152578和miR-29a在伊朗患者结直肠癌治疗前阶段的诊断价值。
在本研究中，收集了30份肿瘤组织样本和30份相邻健康组织样本，并使用Trizol试剂盒提取RNA。随后，使用实时PCR分析候选微小RNA和LncRNAs的相对表达。然后使用REST软件分析获得的基因表达数据。
在本研究中，发现肿瘤组织中LncRNA-xloc-000303的表达与健康组织相比显著增加（p < 0.001）。此外，分析显示lncRNA-LOC152578的表达水平在肿瘤组织中与健康组织相比有所增加（p = 0.57），尽管这些变化无统计学意义。hsa-miR-29a表达分析结果表明，与健康组织相比，肿瘤组织中表达下调；然而，这种变化也无统计学意义（p = 0.34）。
结果表明，与相邻健康组织相比，癌组织中LncRNA-xloc-000303的表达变化显著，提示其有可能作为结直肠癌诊断的生物标志物。然而，需要进一步研究评估lncRNA-LOC152578和hsa-miR-29a的生物标志物特异性。本研究在伊朗人群中进行，其结果未来可用于结直肠癌预防和治疗的个性化医疗。
